| Literature DB >> 22666399 |
Yan Zhang1, Meng-Yun Wang, Jing He, Jiu-Cun Wang, Ya-Jun Yang, Li Jin, Zhi-Yu Chen, Xue-Jun Ma, Meng-Hong Sun, Kai-Qin Xia, Xiao-Nan Hong, Qing-Yi Wei, Xiao-Yan Zhou.
Abstract
BACKGROUND: Non-Hodgkin's lymphoma (NHL) has been reported to be associated with autoimmune and pro-inflammatory response, and genetic polymorphisms of candidate genes involved in autoimmune and pro-inflammatory response may influence the susceptibility to NHL. To evaluate the role of such genetic variations in risk of NHL, we conducted a case-control study of 514 NHL patients and 557 cancer-free controls in a Chinese population.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22666399 PMCID: PMC3362607 DOI: 10.1371/journal.pone.0037846
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of Non-Hodgkin’s lymphoma cases and cancer-free controls.
| Variables | Cases No. (%) | Controls No. (%) |
|
| All subjects | 514 (100) | 557 (100) | |
| Age (years) | 0.895 | ||
| Median (Range) | 50.5 (15–85) | 51.0 (20–85) | |
| <40 | 129 (25.10) | 131 (23.52) | |
| 40–60 | 269 (52.33) | 299 (53.68) | |
| >60 | 116 (22.57) | 127 (22.80) | |
| Sex | 0.830 | ||
| Male | 329 (64.0) | 353 (63.4) | |
| Female | 185 (36.0) | 204 (36.6) | |
| Smoking status | <0.0001 | ||
| Smoker | 101 (25.7) | 232 (43.4) | |
| Non-smoker | 292 (74.3) | 303 (56.6) | |
| Missing | 121 | 22 | |
| Pack-years | <0.0001 | ||
| 0 | 292 (74.3) | 302 (56.4) | |
| 0–25 | 64 (16.3) | 171 (32.0) | |
| >25 | 37 (9.4) | 62 (11.6) | |
| Missing | 121 | 22 | |
| Alcohol use | 0.0001 | ||
| Yes | 58 (14.8) | 134 (25.0) | |
| No | 335 (85.2) | 401 (75.0) | |
| Missing | 121 | 22 | |
| BMI (kg/m2) | <0.0001 | ||
| Median | 22.8 | 23.7 | |
| <18.5 | 29 (6.9) | 21 (3.8) | |
| 18.5–24.0 | 253 (59.8) | 273 (49.0) | |
| >24.0 | 141 (33.3) | 263 (47.2) | |
| Missing | 91 | 0 | |
| Subtype | |||
| B cell lymphoma | 336 (65.4) | – | |
| DLBCL | 233 (45.3) | – | |
| FL | 52 (10.1) | – | |
| Other B cell NHL | 51 (9.9) | – | |
| T cell lymphoma | 178 (34.6) | – | |
| NK/T | 146 (28.4) | – | |
| Other T cell NHL | 32 (6.2) | – | |
| Ann Arbor Stage | – | ||
| I–II | 322 (62.6) | – | |
| III–IV | 192 (37.4) | – |
value of the comparison with a two-sided Chi-square test.
Genotypes distributions of the selected functional polymorphisms among NHL cases and cancer-free controls and their associations with NHL risk.
| Genotyping | Cases | Controls |
| Crude OR (95% CI) |
| Adjusted OR |
| ||||
| n | % | n | % | ||||||||
|
| 0.590 | ||||||||||
| TT | 315 | 61.3 | 358 | 64.3 | 1.00 | 1.00 | |||||
| CT | 183 | 35.6 | 182 | 32.7 | 1.14 (0.89–1.48) | 0.305 | 1.10 (0.82–1.47) | 0.531 | |||
| CC | 16 | 3.1 | 17 | 3.0 | 1.07 (0.53–2.15) | 0.850 | 0.75 (0.33–1.70) | 0.495 | |||
| CT/CC | 199 | 38.7 | 199 | 35.7 | 0.312 | 1.14 (0.89–1.46) | 0.312 | 1.06 (0.80–1.41) | 0.667 | ||
|
| 0.238 | ||||||||||
| GG | 125 | 24.3 | 161 | 28.9 | 1.00 | 1.00 | |||||
| AG | 275 | 53.5 | 280 | 50.3 | 1.26 (0.95–1.68) | 0.108 | 1.30 (0.94–1.81) | 0.112 | |||
| AA | 114 | 22.2 | 116 | 20.8 | 1.27 (0.89–1.79) | 0.185 | 1.30 (0.88–1.94) | 0.188 | |||
| AG/AA | 389 | 75.7 | 396 | 71.1 | 0.090 | 1.26 (0.96–1.66) | 0.090 | 1.30 (0.96–1.78) | 0.094 | ||
|
| 0.279 | ||||||||||
| TT | 226 | 44.0 | 269 | 48.3 | 1.00 | 1.00 | |||||
| GT | 228 | 44.3 | 235 | 42.2 | 1.15 (0.90–1.49) | 0.267 | 1.23 (0.92–1.65) | 0.158 | |||
| GG | 60 | 11.7 | 53 | 9.5 | 1.35 (0.89–2.03) | 0.154 | 1.46 (0.92–2.31) | 0.106 | |||
| GT/GG | 288 | 56.0 | 288 | 51.7 | 0.156 | 1.19 (0.94–1.51) | 0.156 | 1.28 (0.97–1.68) | 0.083 | ||
|
| 0.801 | ||||||||||
| GG | 322 | 62.6 | 338 | 60.7 | 1.00 | 1.00 | |||||
| AG | 166 | 32.3 | 190 | 34.1 | 0.92 (0.71–1.19) | 0.512 | 0.93 (0.69–1.25) | 0.631 | |||
| AA | 26 | 5.1 | 29 | 5.2 | 0.94 (0.54–1.63) | 0.829 | 0.92 (0.48–1.76) | 0.792 | |||
| AG/AA | 192 | 37.4 | 219 | 39.3 | 0.509 | 0.92 (0.72–1.18) | 0.509 | 0.93 (0.70–1.23) | 0.607 | ||
|
| 0.769 | ||||||||||
| CC | 390 | 75.9 | 412 | 74.0 | 1.00 | 1.00 | |||||
| CG | 116 | 22.6 | 136 | 24.4 | 0.90 (0.68–1.20) | 0.472 | 0.93 (0.67–1.29) | 0.645 | |||
| GG | 8 | 1.5 | 9 | 1.6 | 0.94 (0.36–2.46) | 0.898 | 1.19 (0.39–3.68) | 0.760 | |||
| CG/GG | 124 | 24.1 | 145 | 26.0 | 0.472 | 0.90 (0.69–1.19) | 0.473 | 0.94 (0.68–1.29) | 0.705 | ||
|
|
| ||||||||||
| CC | 293 | 57.0 | 381 | 68.4 | 1.00 | 1.00 | |||||
| CT | 180 | 35.0 | 156 | 28.0 |
|
|
|
| |||
| TT | 41 | 8.0 | 20 | 3.6 |
|
|
|
| |||
| CT/TT | 221 | 43.0 | 176 | 31.6 |
|
|
|
|
| ||
Statistically significant results (P<0.05) are highlighted in bold.
ORs were obtained from logistic regression models with adjustment for age, sex, smoking status, alcohol use and BMI.
Two-sided Chi-square test for distribution of three genotypes.
Two-sided Chi-square test for distribution of combined genotypes.
Stratification analysis of the association between TNFAIP8 rs1045241C>T and NHL risk.
| Variables | CT+TT (cases/controls) | CC (cases/controls) | P | OR (95%CI) | P | |||
| n | % | n | % | Crude | Adjusted | |||
| All subjects | 221/176 | 43.0/31.6 | 293/381 | 57.0/68.4 |
|
|
| |
| Age (year) |
| |||||||
| <40 | 56/42 | 43.3/32.1 | 73/89 | 56.6/67.9 | 0.259 | 1.63(0.98–2.70) | 1.43(0.77–2.67) | |
| 40–60 | 119/81 | 44.2/27.1 | 150/218 | 55.8/72.9 |
|
|
| |
| >60 | 46/53 | 39.7/41.7 | 70/74 | 60.3/58.3 | 0.840 | 0.92(0.55–1.53) | 0.94(0.51–1.72) | |
| Sex | 0.340 | |||||||
| Male | 143/106 | 43.5/30.0 | 186/247 | 56.5/70.0 |
|
|
| |
| Female | 78/70 | 42.2/34.3 | 107/134 | 57.8/65.7 |
|
|
| |
| Smoking status | 0.060 | |||||||
| Never | 137/101 | 46.9/33.7 | 155/201 | 53.1/66.3 |
|
|
| |
| ≤25 pack-year | 31/47 | 48.4/27.5 | 33/124 | 51.6/72.5 |
|
|
| |
| >25 pack-year | 18/21 | 48.6/33.9 | 19/41 | 51.4/66.1 | 0.145 | 1.85(0.81–4.25) | 2.06(0.85–5.02) | |
| Missing | 35/7 | 28.9/31.8 | 86/15 | 71.1/68.2 |
|
|
| |
| Drinking status | 0.360 | |||||||
| Yes | 29/38 | 50/28.4 | 29/96 | 50/71.6 |
|
|
| |
| No | 157/131 | 46.9/32.7 | 178/270 | 53.1/67.3 |
|
|
| |
| Missing | 35/7 | 28.9/31.8 | 86/15 | 71.1/68.2 | – | – | – | |
| BMI(kg/m2) | 0.240 | |||||||
| <18.5 | 9/4 | 31.0/19.1 | 20/17 | 69.0/80.9 | 0.340 | 1.91(0.50–7.33) | 1.62(0.37–7.05) | |
| 18.5–24.0 | 117/93 | 46.2/34.1 | 136/180 | 53.8/65.9 |
|
|
| |
| >24.0 | 70/79 | 49.6/30.0 | 71/184 | 50.4/70.0 |
|
|
| |
| Missing | 25/0 | 27.5/0 | 66/0 | 72.5/0 | – | – | – | |
| Ann Arbor Stage |
| |||||||
| I– II | 137/176 | 42.5/31.6 | 185/381 | 57.5/68.4 |
|
|
| |
| III–IV | 84/176 | 43.7/31.6 | 108/381 | 56.3/68.4 |
|
|
| |
| Subtype | 0.490 | |||||||
| B cell NHL | 140/176 | 41.7/31.6 | 196/381 | 58.3/68.4 |
|
|
| |
| DLBCL | 100/176 | 42.9/31.6 | 133/381 | 57.1/68.4 |
|
|
| |
| FL | 29/176 | 55.8/31.6 | 23/381 | 44.2/68.4 |
|
|
| |
| T cell NHL | 81/176 | 45.5/31.6 | 97/381 | 54.5/68.4 |
|
|
| |
| NK/T | 11/176 | 21.6/31.6 | 40/381 | 78.4/68.4 | 0.137 | 0.59(0.30–1.19) | 0.79(0.27–2.33) |
Statistically significant results (P<0.05) are highlighted in bold.
P value of the comparison with a two-sided Chi-square test.
ORs were obtained from logistic regression models with adjustment for age, sex, smoking status, alcohol use and BMI.
P value of the heterogeneity assumption with a Chi-square-based Q-test.